

COVID-19 Vaccine Information Brief

March 4, 2022

Changes to the document from the previous version are highlighted in yellow.

IMPORTANT/NEW COVID-19 Vaccine Information

- J&J COVID-19 Vaccine Availability and Ordering
- IRIS COVID-19 Provider Vaccine Inventory Management
- COVID-19 Quick Reference Guide
- Interim Clinical Considerations for Use of COVID-19 Vaccines
- Pfizer COVID-19 Vaccine Medical Updates on Current & Immunization Site Training
- Vaccine Expiration Date Resources
- V-Safe After Vaccination Health Checker - New Poster

J&J COVID-19 Vaccine Availability and Ordering

CDC has informed IDPH there is currently no plan to increase or replenish J&J vaccine ordering thresholds. Currently, there are over 18,000 doses of J&J vaccine in inventory across Iowa. Given the large amount of inventory already available, IDPH will no longer include J&J vaccine in the Vaccine Allocation Survey. Healthcare providers are strongly encouraged to use existing vaccine inventory and to coordinate redistribution among healthcare providers.

The redistribution of COVID-19 vaccines and the physical transfer of vaccine between COVID-19 vaccination providers should only occur after receiving approval from the IDPH Immunization Program. COVID-19 vaccines may only be redistributed between IDPH approved COVID-19 Providers. Questions regarding COVID-19 vaccine redistribution and the transfer of COVID-19 vaccine can be directed to 1-800-831-6293 ext. 1 or COVID19Vaccine@idph.iowa.gov.

IRIS COVID-19 Provider Vaccine Inventory Management

IRIS vaccine inventory management is a critical component of the pandemic vaccine response. All COVID-19 Vaccine Providers are required to report COVID-19 vaccine doses administered to IRIS which deducts from IRIS inventory. Maintaining accurate inventory impacts the state's ability to report accurate inventory to federal partners. Additionally, this also impacts the state's vaccine thresholds and the amount of vaccine available for all providers. **Providers should make it a practice to regularly check inventory for expired vaccine and immediately remove expired inventory to prevent it from being administered.** Please review these IRIS inventory management best practices to ensure accurate vaccine inventory.

- Ensure Vaccine Redistributions are accurately reported.
 - All COVID-19 vaccine transfers between providers MUST be completed and approved by IDPH. Please see the [Vaccine Redistribution Instructions](#).
 - Providers should NOT physically transfer COVID-19 vaccine without prior IDPH approval.
- Verify all data entry in IRIS is up to date.

- Doses administered are required to be reported to IRIS within 24 hours of vaccine administration.
- Verify data exchange between IRIS and the organization's Electronic Health Record (EHR) has worked appropriately.
 - IRIS Admin users can use the [Doses Not Deducted Report](#) to view and update doses of COVID-19 vaccines not deducted from IRIS inventory.
- Report vaccine wastage in IRIS.
 - Verify all vaccine wastage is documented appropriately using the approved adjustment reasons included in the [Adjusting COVID-19 Vaccine Inventory for Wastage](#) instructions.
 - **VACCINE WASTAGE ADJUSTMENT REASONS CANNOT BE USED TO CORRECT VACCINE INVENTORY FOR UNACCOUNTED DOSES.**

If you have questions regarding IRIS and vaccine inventory, contact the IRIS Help Desk at 1-800-374-3958.

COVID-19 Quick Reference Guide

The quick reference guide provides basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccine products in the United States. For additional information and detailed clinical guidance go to the manufacturers' website and CDC's web pages listed on the guide.

Link to guide:

<https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-quick-reference-guide-2pages.pdf>

Interim Clinical Considerations for Use of COVID-19 Vaccines

[COVID-19 vaccination guidance](#) provides information to help vaccine providers determine the optimal interval between the first and second dose of an mRNA vaccine series, based on the individual patient.

It's important to note this update does not apply to everyone.

- Providers should continue to recommend the 3-week or 4-week interval for people who are moderately or severely immunocompromised, adults ages 65 years and older, and others who may need early protection due to concern about an increased risk of severe illness from COVID-19 or high levels of community transmission.
- People ages 12 years and older with moderate or severe immunocompromise should receive three doses in their mRNA primary vaccine series and should receive a booster dose with an mRNA vaccine at least 3 months after completing their third primary series dose.

Regardless of the interval between the first and second dose, mRNA vaccines are highly effective at reducing the risk of hospitalization and serious complications from COVID-19 infection. And people who have already received their primary mRNA series at the 3-week or 4-week interval remain well-protected—especially if they have received a booster dose.

Primary series vaccine manufacturer	Age group	Number of doses in primary series	Number of booster doses	Interval between 1 st and 2 nd dose *	Interval between primary series and booster dose
Pfizer-BioNTech	5–11 years	2	NA	3 weeks	N/A
Pfizer-BioNTech	≥12 years	2	1	3-8 weeks**	≥5 months
Moderna	≥18 years	2	1	4-8 weeks**	≥5 months
Janssen	≥18 years	1	1	NA	≥2 months

*For the vaccination schedule for people who are moderately or severely immunocompromised, see [Table 3](#).

**An 8-week interval may be optimal for people ages 12 years through 64 years, and especially for males ages 12 through 39 years, who are not moderately or severely immunocompromised. A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second dose remains the recommended interval for: people who are moderately or severely immunocompromised; adults ages 65 years and older; and others who need early protection due to increased concern about community transmission or risk of severe disease.

Updated COVID-19 Vaccine Web Resources

- [Interim Clinical Care Considerations for COVID-19 Vaccination](#)
- [COVID-19 Vaccine Booster Shots](#)
- [COVID-19 Vaccines are Effective](#)
- [COVID-19 Vaccines for People with Allergies](#)

Pfizer COVID-19 Vaccine Medical Updates on Current & Immunization Site Training

At this time, the Medical Affairs team is continuing to educate providers on Purple, Gray, and Orange caps as well as medical updates.

Session topics include:

- Use of each vaccine presentation, including storage, handling, preparation, and administration for:
- Ages 5 through 11 Years: **DILUTE BEFORE USE/Orange Cap**
- Ages 12 Years and Older:
- **DO NOT DILUTE/Gray Cap**
- **DILUTE BEFORE USE/Purple Cap**
- Recent medical updates regarding the vaccine
- An overview of healthcare provider resources
- Question and answer session

Please click on the links below to join the sessions at the designated times.

Date & Time	Password
Attendee link – Tuesday, March 8 - 3pm ET	yMMMMnf5U44
Attendee link – Wednesday, March 9 - 12pm ET	2nWpjWa5H8B

Attendee link – Thursday, March 10 - 12 pm ET	YMeTxT4qf43
---	-------------

Vaccine Expiration Date Resources

Always be sure to check the manufacturer's website to obtain the most up-to-date expiration dates for COVID-19 vaccines. It is important for healthcare providers to update vaccine expiration dates in IRIS. Questions regarding IRIS vaccine inventory and adjusting expiration dates can be directed to the IRIS Helpdesk at 800-374-3958.



For EUA COVID-19 vaccines that do not have a final expiration date, the CDC has set an expiration date of **12/31/2069 to serve as a placeholder date**. Such vaccines have a dynamic expiration date, which can change over time as additional stability data become available. This placeholder date, which is far in the future, is intended to serve as a prompt for the provider to check the latest expiry information on the manufacturer's website. **It is important for healthcare providers to update vaccine expiration dates in IRIS.**

The Pfizer COVID-19 vaccine:

It is important for all healthcare providers to double check all shelf life extensions for all Pfizer products.

Pfizer does not have an expiration date look up tool for these vaccines. **The date on the label is NOT the expiration date, instead, each vial has the lot number and date of manufacture printed on the label.** Pfizer does provide guidance for expiration dates on their [website](#).

- Regardless of storage condition, **GRAY CAP** and **ORANGE CAP** vaccine vials should not be used after 9 months from the **date of manufacture** printed on the vial and cartons.
- The **PURPLE CAP** vaccine vials with an **expiry date** of September 2021 - February 2022 (printed on the label) may remain in use for 3 months beyond the printed date if vials are maintained in approved storage conditions (-90°C to -60°C, -130°F to -76°F).
- Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 **(ORANGE CAP)** years of age may be stored at refrigerated temperatures between 2°C and 8°C (36°F and 46°F) for up to 10 weeks. **Vaccine initially distributed is nearing or has met the 10-week beyond-use date (BUD).**
 - **Reminders for providers:**
 - Vaccine may be stored in a refrigerator unit between 2°C and 8°C (36°F and 46°F) for up to 10 weeks.
 - Do NOT use vaccines stored in the refrigerator after 10 weeks. Discard appropriately.
 - Use a tracking system to ensure the vaccine is not used after the BUD. CDC has tracking labels to monitor storage times at [Pfizer-BioNTech COVID-19 Vaccine \(5 Through 11 Years of Age\) | CDC](#)

 Expiry information for Ages 5 through 11 DILUTE BEFORE USE Orange Cap presentation and Ages 12 years and older DO NOT DILUTE Gray Cap presentation		 Expiry information for Ages 12 years and older DILUTE BEFORE USE Purple Cap presentation	
Printed Manufacturing Date	9-Month Expiry Date	Printed Expiry Date	Updated Expiry Date
06/2021	28-Feb-2022	September 2021	December 2021
07/2021	31-Mar-2022	October 2021	January 2022
08/2021	30-Apr-2022	November 2021	February 2022
09/2021	31-May-2022	December 2021	March 2022
10/2021	30-Jun-2022	January 2022	April 2022
11/2021	31-Jul-2022	February 2022	May 2022
12/2021	31-Aug-2022		
01/2022	30-Sep-2022		
02/2022	31-Oct-2022		

Janssen COVID-19 vaccine: The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:

- Scan the QR code located on the outer carton, or
- Call 1-800-565-4008, or
- Go to www.vaxcheck.inj/

Moderna COVID-19 vaccine:

The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:

- Scan the QR code located on the outer carton, or
- Go to www.modernatx.com/covid19vaccine-eua/

CDC's [COVID-19 Vaccine Expiration Date Tracking Tool](#) can help providers keep track of the expiration date by lot number.

J&J/Janssen		Moderna		Pfizer	
Lot Number	Expiration	Lot Number	Expiration	Lot Number	Expiration
215C21A	3/8/2022	939916	3/9/2022	30155BA	3/31/2022
1822811	3/20/2022	939899	3/10/2022	FF2587	3/31/2022
203F21A	3/21/2022	058E21A	3/10/2022	FF2593	3/31/2022
204F21A	3/22/2022	939917	3/10/2022	FF2588	3/31/2022
218C21A	4/9/2022	059E21A	3/11/2022	FF2590	3/31/2022
1855194	4/9/2022	939918	3/12/2022	FF8841	3/31/2022
211D21A	4/11/2022	002F21A	3/14/2022	FF2589	3/31/2022
213D21A	4/11/2022	052E21A	3/15/2022	FF8839	3/31/2022
1855191	4/11/2022	003F21A	3/15/2022	FH8020	4/30/2022
220C21A	4/11/2022	939901	3/15/2022	FK5127	4/30/2022
208D21A	4/24/2022	053E21A	3/15/2022	FJ5682	4/30/2022
1855835	4/27/2022	004F21A	3/17/2022		
1855190	4/27/2022	939902	3/17/2022		
219C21-2A	5/2/2022	061E21A	3/17/2022		
202D21A	5/2/2022	062E21A	3/18/2022		
204D21A	5/3/2022	939903	3/18/2022		
1855836	5/7/2022	939919	3/18/2022		
201F21A	5/8/2022	012H21B	3/18/2022		

V-safe After Vaccination Health Checker

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after an individual receives a COVID-19 vaccination. V-safe web pages feature information on how to register and complete a v-safe health check-in (including step-by-instructions with images), troubleshooting, FAQs, and contact information for technical support. These web pages will be continuously updated with additional resources.

- V-safe information sheet and poster: posted on the vaccine webpage and available in 5 languages: English, Spanish, Korean, Vietnamese, and Simplified Chinese
- [V-safe after vaccination health checker website](#)
- [V-safe Print Resources](#)
- [V-safe Poster-11x17](#)
- [Vaccine Adverse Event Reporting System \(VAERS\)](#)